VISTA-mediated immune evasion in cancer.

Autor: Zhang RJ; Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN, USA.; Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Kim TK; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.; Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.; Vanderbilt Ingram Cancer Center, Nashville, TN, 37232, USA. tae.k.kim@vumc.org.
Jazyk: angličtina
Zdroj: Experimental & molecular medicine [Exp Mol Med] 2024 Nov; Vol. 56 (11), pp. 2348-2356. Date of Electronic Publication: 2024 Nov 01.
DOI: 10.1038/s12276-024-01336-6
Abstrakt: Over the past decade, V-domain immunoglobulin suppressor of T-cell activation (VISTA) has been established as a negative immune checkpoint molecule. Since the role of VISTA in inhibiting T-cell activation was described, studies have demonstrated other diverse regulatory functions in multiple immune cell populations. Furthermore, its relevance has been identified in human cancers. The role of VISTA in cancer immune evasion has been determined, but its mechanisms in the tumor microenvironment remain to be further elucidated. Understanding its contributions to cancer initiation, progression, and resistance to current treatments will be critical to its utility as a target for novel immunotherapies. Here, we summarize the current understanding of VISTA biology in cancer.
Competing Interests: Competing interests: R.J.Z. does not have any conflict of interest. T.K.K. is a consultant for Agenus and Immunobiome.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: